Last updated: 2026-09-29 18:22:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Merck & Co., Inc. (MRK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $148.90, with a market capitalisation of $366.84B and a P/E ratio of 115.61. Over the past 52 weeks, its price has ranged from $78.03 to $156.92. This page covers its latest market performance, valuation, price trends and company information.
$366.84B | |
$148.17 | |
$156.92 | |
$20.05 | |
$148.69 | |
3.57M | |
9.71M | |
115.61 | |
$156.92 | |
$78.03 | |
2.26% | |
-- |
Merck & Co., Inc. (MRK) is currently trading at $148.90 as of 2026-09-29 18:06:56, up 0.14% ($0.21) from the previous close of $148.69
During today's regular trading session, MRK has traded between $20.05 and $156.92, with a trading volume of 3.57M shares. The current price is near the upper end of today's range.
Over the past seven days, Merck & Co., Inc. (MRK) moved from $149.50 to $148.90, representing a decline of 0.40% ($0.60).
The stock traded between $145.60 and $153.57 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 7.88 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 89.8%
MRK is currently trading at $148.90, placing it 89.8% of the way from its 52-week low of $78.03 to its 52-week high of $156.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 75000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Merck & Co., Inc. (MRK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.